EE50 A Cost-Consequence Model of Using the 21-Gene Breast Recurrence Score Assay to Identify Patients With Early-Stage Node-Positive Breast Cancer Who Benefit From Adjuvant Chemotherapy in the Netherlands

Machielsen, P; Jongh, FE de; Drost, P; Simons, M; Spoorendonk, JA

doi:10.1016/j.jval.2022.09.303

Value in Health

2022

DOI: 10.1016/j.jval.2022.09.303

|View full text |Cite

EE50 A Cost-Consequence Model of Using the 21-Gene Breast Recurrence Score Assay to Identify Patients With Early-Stage Node-Positive Breast Cancer Who Benefit From Adjuvant Chemotherapy in the Netherlands

P Machielsen¹,

FE de Jongh

P Drost³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands

Simons,

Machielsen,

Spoorendonk

et al. 2024

Journal of Medical Economics

View full text Add to dashboard Cite

A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands

Simons,

Machielsen,

Spoorendonk

et al. 2024

Journal of Medical Economics

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

EE50 A Cost-Consequence Model of Using the 21-Gene Breast Recurrence Score Assay to Identify Patients With Early-Stage Node-Positive Breast Cancer Who Benefit From Adjuvant Chemotherapy in the Netherlands

Cited by 1 publication

References 0 publications

A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands

A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands

Contact Info

Product

Resources

About